<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229602</url>
  </required_header>
  <id_info>
    <org_study_id>FY-CP-06-201909-01</org_study_id>
    <nct_id>NCT04229602</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules in Chinese Healthy Volunteers</brief_title>
  <official_title>Bioequivalence Study of Venlafaxine Hydrochloride Sustained-Release Capsules and EFEXOR® XR Under Fed Conditions in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the human bioequivalence of two Venlafaxine
      Hydrochloride Sustained-Release Capsules (75 mg) .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the human bioequivalence of Venlafaxine
      Hydrochloride Sustained-Release Capsules (75 mg) produced by Beijing Winsunny Pharmaceutical
      Co., Ltd and EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer
      Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD), as well as the safety of
      the tested preparation, and to provide basis for the evaluation of the quality and efficacy
      consistency of the tested preparation and the reference preparation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">July 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>Cmax - Maximum Observed Concentration (of Venlafaxine in Plasma)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC0-t</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC0-∞</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>AUC0-∞- Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>Venlafaxine Hydrochloride Sustained-Release Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of Hydrochloride Sustained-Release Capsules 75 mg under Fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: EFEXOR® XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of EFEXOR® XR 75mg under Fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine Hydrochloride Sustained-Release Capsules 75 mg</intervention_name>
    <description>A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.</description>
    <arm_group_label>Venlafaxine Hydrochloride Sustained-Release Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EFEXOR® XR</intervention_name>
    <description>EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)</description>
    <arm_group_label>Active Comparator: EFEXOR® XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects are fully informed and voluntarily consent to participate in this study;

          2. Healthy adult volunteers of ≥18 years old and ≤ 65 years old, male or female;

          3. Body weight ≥ 50.0 kg for male and 45.0 kg for female;

          4. Subjects are able to communicate well with the investigator and to understand and
             comply with the requirements of the study.

        Exclusion Criteria:

          1. Subjects enroll in other clinical trials and take corresponding experimental drugs
             within 90 days before the trial, or participate in other clinical trials;

          2. The results of physical examination, vital signs examination, clinical laboratory
             examination (blood routine, urine routine, blood biochemistry, coagulation function,
             immunity 8 items, blood pregnancy (female only)), 12-lead electrocardiogram (ECG) are
             clinical significant;

          3. Any previous history and present medical history that may affect the safety of the
             trial or the in-vivo process of the drug, especially a history of liver, kidney,
             endocrine, cardiovascular, nervous, gastrointestinal, lung, tumor, immune, skin, blood
             or metabolic disorders that the investigator considers clinically significant;

          4. Any history of surgery or trauma that may affect the safety of the test or the in-vivo
             process of the drug;;

          5. Subjects have depression, mania and other mental disorders, or have suicidal
             tendencies;

          6. Subjects have the history of angle-closure glaucoma;

          7. Heavy smokers (average daily smoking of more than 5 cigarettes in the 90 days before
             the trial), heavy drinkers (average weekly drinking of more than 14 units of alcohol
             in the 90 days before the trial, 1 unit =360 mL beer or 45 mL 40% spirits or 150 mL
             wine), and subjects who could not promise to quit smoking and drinking during the
             experiment;

          8. Subjects had taken any alcoholic product within 24 hours before the test, or had
             tested positive for alcohol breath test;

          9. Allergic to any component of venlafaxine hydrochloride sustained-release capsules, or
             with a history of specific allergies (asthma, urticaria, eczema, etc.), or allergic
             constitution (such as allergic to two or more drugs or food);

         10. Lactose intolerance (a history of diarrhea from drinking milk);

         11. Previous history of drug use, drug abuse, or positive urine drug screening;

         12. Subjects who have donated blood or lost blood equal to or more than 200 mL within 90
             days before the test, received blood transfusion or used blood products, or intend to
             donate blood or blood components during or within 3 months after the test;

         13. Nursing woman;

         14. Subjects planned parenthood, unwillingness or inability to use effective
             contraception, within 30 days before the trial (for women), and within six months
             after the end of the trial;

         15. Subjects who have taken any medicine (including Chinese herbal medicine) and health
             care products within 14 days before the test;

         16. Subjects who have taken any medicine that interacts with the drug or alters liver
             enzyme activity within 30 days prior to the trial, such as cimetidine, haloperidol,
             ketoconazole, clot-disrupting drugs (such as non-steroidal anti-inflammatory drugs,
             aspirin and warfarin), Monoamine oxidase inhibitors (such as phenyledrine,
             phenylamine, isazolid, isazolid, moclobemide, bromofaramine, nyalamide, tloxadone,
             defloxadone, slegiline, linezolid, or methylene blue for intravenous use), similar to
             other serotonin drugs (including triptans, selective serotonin reuptake inhibitors
             (SSRIs), other serotonin and norepinephrine reuptake inhibitors (SNRIs), lithium,
             sibutramine, tramadol or st John's wort, and tryptophan supplements) etc ;

         17. Subjects who have eaten special diet (including grapefruit and/or food or drink rich
             in xanthine derivatives or alcohol, such as tea and coffee, etc.) or have other
             factors affecting drug absorption, distribution, metabolism and excretion within 14
             days before the test;

         18. Subjects who have special requirements on diet and cannot accept unified diet;

         19. Subjects who have the difficulty in venous blood, or can not tolerate venipuncture, or
             have a history of dizziness;

         20. Subjects who need to drive and operate machines or engage in other potentially
             dangerous activities during the test;

         21. Other situations that the researchers considered unsuitable to enroll the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Wu, Dr</last_name>
    <phone>0086-10-58268486</phone>
    <email>trdrug@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institution of Drug Clinical Trials</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wu, Dr</last_name>
      <phone>0086-10-58268486</phone>
      <email>trdrug@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 31, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

